

DERMATOLOGY PRESCRIPTION FORM (Part 2)

Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to the pharmacy. Prescribers are reminded patients may choose any pharmacy of their choice.

Owl Specialty Pharmacy
 1010 E. Arrow Hwy., Covina, CA 91724
 Phone: 626-209-8169 Fax: 626-209-8171 or 855-817-9523
www.owlspecialty.com



Patient Information: please provide a copy of the patient's insurance card or information

| | | | | | |
|--|---------------------------|--------------|--|------------------|---------------|
| Patient Name: | | DOB: | Gender: <input type="checkbox"/> F <input type="checkbox"/> M | HT: | WT: |
| Address: | | City: | State: | Zip Code: | Phone: |
| Insurance: | Subscriber's name: | | ID#: | Group #: | |
| Allergies: <input type="checkbox"/> NKDA <input type="checkbox"/> List allergies: | | | | | |

Clinical Diagnosis: please fax or email relevant clinical notes, labs, tests and previous medical history to expedite prior authorization

| | | |
|---|---|---|
| Diagnosis / ICD-10: <input type="checkbox"/> Psoriasis / _____ <input type="checkbox"/> Psoriatic Arthritis / _____ <input type="checkbox"/> Chronic Idiopathic Urticaria / _____ <input type="checkbox"/> Hidradenitis Suppurativa / _____ <input type="checkbox"/> Other: _____ | | |
| PSO/PSA | Diagnosed with: <input type="checkbox"/> CHF <input type="checkbox"/> Latex Allergy <input type="checkbox"/> MS <input type="checkbox"/> Hep B/C <input type="checkbox"/> Malignancy | Affected areas: <input type="checkbox"/> palms <input type="checkbox"/> soles <input type="checkbox"/> head <input type="checkbox"/> neck <input type="checkbox"/> genitalia |
| | TB/PPD test: Y / N Date of negative test: _____ | % of BSA affected: |
| | <input type="checkbox"/> Patient is currently on therapy (Start date ___/___/___) Prior Therapies: Please include biologics, MTX, PUVA, topicals, UVB/NBUVB and trials, including dates of treatment and reasons for discontinuation. | |

| Medication | Dose / Strength | Directions | Quantity | Refills |
|-----------------------------------|---|--|------------|---------|
| <input type="checkbox"/> Ilumya™ | <input type="checkbox"/> 100 mg prefilled syringe | <input type="checkbox"/> 100 mg SC day 0 and 28, then every 12 weeks. | | |
| <input type="checkbox"/> Otezla® | <input type="checkbox"/> Starter Kit | <input type="checkbox"/> Taper per starter pack packaging | | |
| | <input type="checkbox"/> 30 mg tablets | <input type="checkbox"/> 30 mg PO twice daily <input type="checkbox"/> 30 mg PO once daily | #60 #30 | |
| <input type="checkbox"/> Rinvoq® | <input type="checkbox"/> 15 mg tablets | <input type="checkbox"/> 15 mg PO once daily | | |
| | <input type="checkbox"/> 30 mg tablets | <input type="checkbox"/> 30 mg PO once daily | #30 | |
| <input type="checkbox"/> Siliq™ | <input type="checkbox"/> 210 mg/ 1.5 mL single-dose prefilled syringe | <input type="checkbox"/> 210 mg SC day 0, 7 and 14, then every 2 weeks | | |
| <input type="checkbox"/> Simponi® | <input type="checkbox"/> 50 mg/ 0.5 mL SmartJect® autoinjector | <input type="checkbox"/> 50 mg SC every 4 weeks | | |
| | <input type="checkbox"/> 50 mg/ 0.5 mL prefilled syringe | | | |
| | <input type="checkbox"/> 100 mg/ mL SmartJect® autoinjector | <input type="checkbox"/> 200 mg SC day 0; 100 mg day 7; then 100 mg every 4 weeks | | |
| | <input type="checkbox"/> 100 mg/ mL prefilled syringe | | | |
| <input type="checkbox"/> Skyrizi™ | <input type="checkbox"/> 150 mg/ 1 mL pen | <input type="checkbox"/> Loading dose - 150 mg SC Week 0, Week 4 | | |
| | <input type="checkbox"/> 150 mg/ 1 mL syringe | <input type="checkbox"/> Maintenance dose - 150 mg SC every 12 weeks | | |
| <input type="checkbox"/> Sotyktu® | <input type="checkbox"/> 6mg tablets | <input type="checkbox"/> 6mg PO once daily | #30 | |
| <input type="checkbox"/> Stelara® | <input type="checkbox"/> 45 mg/ 0.5 mL prefilled syringe | <input type="checkbox"/> 45 mg SC days 0, 28 and then every 12 weeks | | |
| | <input type="checkbox"/> 90 mg/ 1 mL prefilled syringe | <input type="checkbox"/> 90 mg SC days 0, 28 and then every 12 weeks | | |
| <input type="checkbox"/> Taltz™ | <input type="checkbox"/> 80 mg/ mL prefilled syringe | <input type="checkbox"/> 160 mg SC (two 80 mg injections) week 0, then 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks | | |
| | <input type="checkbox"/> 80 mg / mL prefilled autoinjector | | | |
| <input type="checkbox"/> Tremfya™ | <input type="checkbox"/> 100 mg / mL prefilled syringe | <input type="checkbox"/> 100 mg SC day 0 and 28, then every 8 weeks | | |
| | | <input type="checkbox"/> 100 mg SC every 8 weeks. | | |
| <input type="checkbox"/> OTHER | | | | |

Prescriber Information

| | | | | | |
|----------------------------|-------------|---------------------|---|-------------|--|
| Prescriber name: | | Phone: | Office contact name: | | |
| Prescriber address: | | City: | State: | Zip: | |
| NPI: | DEA: | Email / Fax: | | | |
| Signature: | | Date: | <input type="checkbox"/> DO NOT SUBSTITUTE | | |

Important Notice: This facsimile transmission is intended to be delivered only to the named recipient(s), and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named recipient, immediately notify the sender at the address and phone number set forth herein and obtain instructions as to properly dispose of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except authority of the sender to the named addressee.